1021950-26-4
1021950-26-4
Chemical Structure
Tyrosine kinase inhibitor
- CAS No.: 1021950-26-4
- Formula:C31H31FN6O5
- Molecular Weight:586.61
IUPAC Name: N-(4-fluorophenyl)-N-(4-((2-((2-morpholinoethyl)carbamoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide
InChIKey: PKOVTRMHYNEBDU-UHFFFAOYSA-N
SMILES: O=C(NC1=CC=C(C=C1)F)C2(CC2)C(NC3=CC=C(C=C3)OC4=C5C(NC(C(NCCN6CCOCC6)=O)=C5)=NC=C4)=O
Biological Activity: Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tyrosine kinase inhibitor | 99.88% | Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tyrosine kinase inhibitor (Standard) | ≥98% | Tyrosine kinase inhibitor (Standard) is the analytical standard of Tyrosine kinase inhibitor (HY-10421). This product is intended for research and analytical applications. Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Foretinib | 99.45% | Foretinib is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Foretinib phosphate | Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cabozantinib S-malate | 99.90% | Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cabozantinib | 99.97% | Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cabozantinib hydrochloride | Cabozantinib hydrochloride is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035 and 1.3 nM, respectively. Cabozantinib hydrochloride displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib hydrochloride shows antiangiogenic activity. Cabozantinib hydrochloride disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cabozantinib-d6 | 98.14% | Cabozantinib-d6 is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Zanzalintinib | 99.91% | Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Canlitinib | 97.09% | Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib has the potential for cancer study. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taligantinib | Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3-Fluoro-desmethyl-cabozantinib | 3-Fluoro-desmethyl-cabozantinib is an BCL6 ligand that can be used in the synthesis of PROTACs, such as SJF-8240 (HY-123961). 3-Fluoro-desmethyl-cabozantinib is also a p38α ligand that can be used to synthesize PROTACs, such as SJFα (HY-114404). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
